GLAUKOS CORP (GKOS) Stock Price, Quote, News and Overview
NYSE:GKOS - New York Stock Exchange, Inc. - US3773221029 - Common Stock - Currency: USD
GKOS Quote, Performance and Key Statistics
125.88
-31.48 (-20.01%)
The current stock price of GKOS is 125.88 USD. In the past month the price decreased by -21.92%. In the past year, price increased by 40.54%.
GKOS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 28.89 | 234.01B | ||
| ISRG | INTUITIVE SURGICAL INC | 80.74 | 211.07B | ||
| BSX | BOSTON SCIENTIFIC CORP | 41.63 | 154.00B | ||
| SYK | STRYKER CORP | 31.4 | 145.92B | ||
| MDT | MEDTRONIC PLC | 16.84 | 115.33B | ||
| BDX | BECTON DICKINSON AND CO | 16.35 | 65.30B | ||
| EW | EDWARDS LIFESCIENCES CORP | 27.98 | 43.23B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 20.29 | 41.62B | ||
| IDXX | IDEXX LABORATORIES INC | 40.25 | 37.07B | ||
| DXCM | DEXCOM INC | 53.81 | 34.68B | ||
| RMD | RESMED INC | 26.21 | 34.03B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 17.5 | 24.02B |
Related stock screener links
About GKOS
Company Profile
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in Aliso Viejo, California and currently employs 907 full-time employees. The company went IPO on 2015-06-25. The company develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.
Company Info
GLAUKOS CORP
1 Glaukos Way
Aliso Viejo CALIFORNIA 92672 US
CEO: Thomas W. Burns
Employees: 907
Company Website: https://www.glaukos.com
Investor Relations: https://investors.glaukos.com/
Phone: 19493679600
GLAUKOS CORP / GKOS FAQ
What is the stock price of GLAUKOS CORP today?
The current stock price of GKOS is 125.88 USD. The price decreased by -20.01% in the last trading session.
What is the ticker symbol for GLAUKOS CORP stock?
The exchange symbol of GLAUKOS CORP is GKOS and it is listed on the New York Stock Exchange, Inc. exchange.
On which exchange is GKOS stock listed?
GKOS stock is listed on the New York Stock Exchange, Inc. exchange.
What is the price forecast or stock price prediction for GLAUKOS CORP stock?
21 analysts have analysed GKOS and the average price target is 163.99 USD. This implies a price increase of 30.27% is expected in the next year compared to the current price of 125.88. Check the GLAUKOS CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is GLAUKOS CORP worth?
GLAUKOS CORP (GKOS) has a market capitalization of 6.94B USD. This makes GKOS a Mid Cap stock.
How many employees does GLAUKOS CORP have?
GLAUKOS CORP (GKOS) currently has 907 employees.
What are the support and resistance levels for GLAUKOS CORP (GKOS) stock?
GLAUKOS CORP (GKOS) has a support level at 125.87. Check the full technical report for a detailed analysis of GKOS support and resistance levels.
Is GLAUKOS CORP (GKOS) expected to grow?
The Revenue of GLAUKOS CORP (GKOS) is expected to grow by 26.68% in the next year. Check the estimates tab for more information on the GKOS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy GLAUKOS CORP (GKOS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GKOS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GKOS, evaluating the profitability, health, valuation and growth aspects
- GLAUKOS CORP (GKOS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- GLAUKOS CORP (GKOS) Sales and EPS estimates to see what analysts future expectations are.
- GLAUKOS CORP (GKOS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- GLAUKOS CORP (GKOS) Insider and Institutional Ownership to learn about the owners and their transactions.
- GLAUKOS CORP (GKOS) Stock Chart to make your own analysis
- GLAUKOS CORP (GKOS) Latest news and press-releases to stay up to date.
Does GLAUKOS CORP (GKOS) stock pay dividends?
GKOS does not pay a dividend.
When does GLAUKOS CORP (GKOS) report earnings?
GLAUKOS CORP (GKOS) will report earnings on 2025-04-29, after the market close.
What is the Price/Earnings (PE) ratio of GLAUKOS CORP (GKOS)?
GLAUKOS CORP (GKOS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.9).
What is the Short Interest ratio of GLAUKOS CORP (GKOS) stock?
The outstanding short interest for GLAUKOS CORP (GKOS) is 6.29% of its float. Check the ownership tab for more information on the GKOS short interest.
GKOS Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to GKOS. When comparing the yearly performance of all stocks, GKOS is one of the better performing stocks in the market, outperforming 81.41% of all stocks.
GKOS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GKOS. While GKOS seems to be doing ok healthwise, there are quite some concerns on its profitability.
GKOS Financial Highlights
Over the last trailing twelve months GKOS reported a non-GAAP Earnings per Share(EPS) of -1.9. The EPS increased by 16.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -16.14% | ||
| ROE | -22.37% | ||
| Debt/Equity | 0.19 |
GKOS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to GKOS. The Buy consensus is the average rating of analysts ratings from 21 analysts.
For the next year, analysts expect an EPS growth of 43.69% and a revenue growth 26.68% for GKOS